Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar 1;51(3):633-7.
doi: 10.1515/cclm-2012-0465.

B Vitamin Therapy for Homocysteine: Renal Function and Vitamin B12 Determine Cardiovascular Outcomes

Affiliations

B Vitamin Therapy for Homocysteine: Renal Function and Vitamin B12 Determine Cardiovascular Outcomes

John David Spence. Clin Chem Lab Med. .

Abstract

Therapy to lower homocysteine with B vitamins does reduce the risk of stroke, if not myocardial infarction. The apparent lack of efficacy of vitamin therapy in most of the large clinical trials was probably determined by the failure to take account of the metabolic deficiency of vitamin B12, which is very common and often missed, and by the failure to take account of impaired renal function. Metabolic B12 deficiency is present in 20% of people over 65 years of age, and in 30% of vascular patients above 70 years, so higher doses of B12 are needed in elderly patients. However, high-dose cyanocobalamin leads to accumulation of cyanide in patients with renal failure. B vitamin therapy is beneficial in patients with good renal function, but harmful in patients with significantly impaired renal function (a glomerular filtration rate <50). It seems likely that in patients with renal impairment, methylcobalamin should be used instead cyanocobalamin.

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

LinkOut - more resources

Feedback